Clinical evaluation of nuclear matrix protein 22 in urine for bladder cancer / 中华泌尿外科杂志
Chinese Journal of Urology
; (12)2001.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-536165
Biblioteca responsável:
WPRO
ABSTRACT
Objective To determine the clinical efficac y of nuclear matrix protein 22(NMP22) as a novel urine marker for bladder cance r. Methods Urine NMP22 values were determined for 18 bla dder cancer patients and 20 urological benign disease patients by an enzyme-lin ked immunosorbent assay (ELISA). Results Median NMP22 va lue for the bladder cancers was 44.3 IU/L vs 5.8 IU/L for urological benign dise ases. The urinary NMP22 values in the bladder cancer group were significantly hi gher than those in the benign condition group (P
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Urology
Ano de publicação:
2001
Tipo de documento:
Artigo